tideglusib tideglusib tideglusib (np-12, np031112) is a potent and irreversible small molecule glycogen synthase kinase 3 (gsk-3) inhibitor. tideglusibidentifiers iupac name 4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione cas number865854-05-3pubchem cid11313622chemspider9488589uniiq747y6tt42chebichebi:147398comptox dashboard (epa)dtxsid90235682 chemical and physical dataformulac19h14n2o2smolar mass334.39 g·mol−13d model (jsmol)interactive image smiles o=c3sn(c1cccc2c1cccc2)c(=o)n3cc4ccccc4 inchi inchi=1s/c19h14n2o2s/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12h,13h2 other gsk inhibitors there are few classes of gsk-inhibitors, including lithium (martinez et al., 2011), the small peptide l803mts10, and members of the thiazolidinedione family, containing inhibitors of gsk-3, such as tdzd-8 (shapira et al., 2007) or tideglusib® (noscira, madrid, and spain), the latter having an irreversible inhibitory effect on gsk-3 (dominguez et al., 2012). the inhibition of the gsk-3 pathways through distinct mechanisms has been associated with a wide range of adverse reactions, ranging from mild, such as vertigo—or diarrhea (del ser et al., 2013)—to very severe, such as hypoglycemia—or tumorigenesis (martinez et al., 2011). the use of tideglusib specifically was associated with mild-moderate adverse reactions, which included transient increases in serum creatine kinase, alt—or ggt—diarrhea, nausea, cough, fatigue, and headache (del ser et al., 2013). in a phase-iia clinical trial, the treatment was discontinued in 35% of all the active subjects, due to such adverse effects (del ser et al., 2013). potential applications tideglusib is under investigation for multiple applications: alzheimer's disease and progressive supranuclear palsy. both clinical trials were discontinued in 2011 (psp) and 2012 (alzheimer's disease) due to lack of efficacy tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. in 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled. tideglusib is being studied in phase ii clinical trials as a treatment for congenital/juvenile-onset myotonic muscular dystrophy type i.